Alamar Biosciences used AAIC 2026 to present data from more than 140 presentations centered on blood-based Alzheimer's biomarkers from its NULISA platform.
New findings highlighted eMTBR-Tau and BD-pTau217 as markers aimed at improving Alzheimer's detection and disease staging through blood tests.
The presentations underscored Alamar's push to expand blood-based biomarker tools as a less invasive approach to identifying and tracking Alzheimer's progression.
With multiple companies launching Alzheimer's diagnostics, which technology will win the race for accuracy?
How will new blood tests that can stage Alzheimer's progression change patient treatment and care?
If a simple blood test can predict Alzheimer's, are our healthcare systems ready for the implications?
NULISA’s Breakthrough at AAIC 2026: Over 140 Presentations Signal a New Era in Alzheimer’s Blood Biomarker Detection
Overview
At the Alzheimer's Association International Conference (AAIC) 2026 in London, Alamar Biosciences' NULISA platform stood out as a major breakthrough in Alzheimer's research. Featured in over 140 scientific presentations, NULISA gained significant attention for its ultra-sensitive, multiplex protein detection capabilities. By analyzing multiple proteins at once, the platform provides deeper insights into complex neurodegenerative diseases. This growing recognition highlights NULISA's crucial role in advancing the understanding and diagnosis of Alzheimer's and dementia, marking it as an increasingly important tool for researchers and clinicians alike.